Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor

Jung Sun Cho, Sung Ho Her, Ju Yeal Baek, Mahn Won Park, Hyoung Doo Kim, Myung Ho Jeong, Young Keun Ahn, Shung Chull Chae, Seung Ho Hur, Taek Jong Hong, Young Jo Kim, In Whan Seong, Jei Keon Chae, Jay Young Rhew, In Ho Chae, Myeong Chan Cho, Jang Ho Bae, Seung-Woon Rha, Chong Jim Kim, Donghoon ChoiYang Soo Jang, Junghan Yoon, Wook Sung Chung, Jeong Gwan Cho, Ki Bae Seung, Seung Jung Park

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) with or without glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with or without Gp IIb/IIIa inhibitor has not been elucidated. Between October 2005 and July 2007, 2,535 patients with ST elevation acute myocardial infarction (STEMI) undergoing PCI in the Korean Acute Myocardial Infarction Registry (KAMIR) were assigned to either of two groups: a group with Gp IIb/IIIa inhibitor (n=476) or a group without Gp IIb/IIIa inhibitor (n=2,059). These groups were further subdivided according to the use of LMWH with low dose UFH (n=219) or UFH alone (n=257). The primary end points were cardiac death or myocardial infarction during the 30 days after the registration. The primary end point occurred in 4.1% (9/219) of patients managed with LMWH during PCI and Gp IIb/IIIa inhibitor and 10.8% (28/257) of patients managed with UFH and Gp IIb/IIIa inhibitor (odds ratio [OR], 0.290; 95% confidence interval [CI], 0.132-0.634; P=0.006). Thrombolysis In Myocardial Infarction (TIMI) with major bleeding was observed in LMHW and UFH with Gp IIb/IIIa inhibitor (1/219 [0.5%] vs 1/257 [0.4%], P=1.00). For patients with STEMI managed with a primary PCI and Gp IIb/IIIa inhibitor, LMWH is more beneficial than UFH.

Original languageEnglish
Pages (from-to)1601-1608
Number of pages8
JournalJournal of Korean Medical Science
Volume25
Issue number11
DOIs
Publication statusPublished - 2010 Nov 1

Fingerprint

Platelet Glycoprotein GPIIb-IIIa Complex
Low Molecular Weight Heparin
Percutaneous Coronary Intervention
Heparin
Myocardial Infarction
ST Elevation Myocardial Infarction
Registries
Odds Ratio
Confidence Intervals
Hemorrhage

Keywords

  • Blood platelets
  • Heparin
  • Myocardial infarction
  • Prognosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor. / Cho, Jung Sun; Her, Sung Ho; Baek, Ju Yeal; Park, Mahn Won; Kim, Hyoung Doo; Jeong, Myung Ho; Ahn, Young Keun; Chae, Shung Chull; Hur, Seung Ho; Hong, Taek Jong; Kim, Young Jo; Seong, In Whan; Chae, Jei Keon; Rhew, Jay Young; Chae, In Ho; Cho, Myeong Chan; Bae, Jang Ho; Rha, Seung-Woon; Kim, Chong Jim; Choi, Donghoon; Jang, Yang Soo; Yoon, Junghan; Chung, Wook Sung; Cho, Jeong Gwan; Seung, Ki Bae; Park, Seung Jung.

In: Journal of Korean Medical Science, Vol. 25, No. 11, 01.11.2010, p. 1601-1608.

Research output: Contribution to journalArticle

Cho, JS, Her, SH, Baek, JY, Park, MW, Kim, HD, Jeong, MH, Ahn, YK, Chae, SC, Hur, SH, Hong, TJ, Kim, YJ, Seong, IW, Chae, JK, Rhew, JY, Chae, IH, Cho, MC, Bae, JH, Rha, S-W, Kim, CJ, Choi, D, Jang, YS, Yoon, J, Chung, WS, Cho, JG, Seung, KB & Park, SJ 2010, 'Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor', Journal of Korean Medical Science, vol. 25, no. 11, pp. 1601-1608. https://doi.org/10.3346/jkms.2010.25.11.1601
Cho, Jung Sun ; Her, Sung Ho ; Baek, Ju Yeal ; Park, Mahn Won ; Kim, Hyoung Doo ; Jeong, Myung Ho ; Ahn, Young Keun ; Chae, Shung Chull ; Hur, Seung Ho ; Hong, Taek Jong ; Kim, Young Jo ; Seong, In Whan ; Chae, Jei Keon ; Rhew, Jay Young ; Chae, In Ho ; Cho, Myeong Chan ; Bae, Jang Ho ; Rha, Seung-Woon ; Kim, Chong Jim ; Choi, Donghoon ; Jang, Yang Soo ; Yoon, Junghan ; Chung, Wook Sung ; Cho, Jeong Gwan ; Seung, Ki Bae ; Park, Seung Jung. / Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor. In: Journal of Korean Medical Science. 2010 ; Vol. 25, No. 11. pp. 1601-1608.
@article{607e986acbf946529258139ed4f0e054,
title = "Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor",
abstract = "The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) with or without glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with or without Gp IIb/IIIa inhibitor has not been elucidated. Between October 2005 and July 2007, 2,535 patients with ST elevation acute myocardial infarction (STEMI) undergoing PCI in the Korean Acute Myocardial Infarction Registry (KAMIR) were assigned to either of two groups: a group with Gp IIb/IIIa inhibitor (n=476) or a group without Gp IIb/IIIa inhibitor (n=2,059). These groups were further subdivided according to the use of LMWH with low dose UFH (n=219) or UFH alone (n=257). The primary end points were cardiac death or myocardial infarction during the 30 days after the registration. The primary end point occurred in 4.1{\%} (9/219) of patients managed with LMWH during PCI and Gp IIb/IIIa inhibitor and 10.8{\%} (28/257) of patients managed with UFH and Gp IIb/IIIa inhibitor (odds ratio [OR], 0.290; 95{\%} confidence interval [CI], 0.132-0.634; P=0.006). Thrombolysis In Myocardial Infarction (TIMI) with major bleeding was observed in LMHW and UFH with Gp IIb/IIIa inhibitor (1/219 [0.5{\%}] vs 1/257 [0.4{\%}], P=1.00). For patients with STEMI managed with a primary PCI and Gp IIb/IIIa inhibitor, LMWH is more beneficial than UFH.",
keywords = "Blood platelets, Heparin, Myocardial infarction, Prognosis",
author = "Cho, {Jung Sun} and Her, {Sung Ho} and Baek, {Ju Yeal} and Park, {Mahn Won} and Kim, {Hyoung Doo} and Jeong, {Myung Ho} and Ahn, {Young Keun} and Chae, {Shung Chull} and Hur, {Seung Ho} and Hong, {Taek Jong} and Kim, {Young Jo} and Seong, {In Whan} and Chae, {Jei Keon} and Rhew, {Jay Young} and Chae, {In Ho} and Cho, {Myeong Chan} and Bae, {Jang Ho} and Seung-Woon Rha and Kim, {Chong Jim} and Donghoon Choi and Jang, {Yang Soo} and Junghan Yoon and Chung, {Wook Sung} and Cho, {Jeong Gwan} and Seung, {Ki Bae} and Park, {Seung Jung}",
year = "2010",
month = "11",
day = "1",
doi = "10.3346/jkms.2010.25.11.1601",
language = "English",
volume = "25",
pages = "1601--1608",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "11",

}

TY - JOUR

T1 - Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor

AU - Cho, Jung Sun

AU - Her, Sung Ho

AU - Baek, Ju Yeal

AU - Park, Mahn Won

AU - Kim, Hyoung Doo

AU - Jeong, Myung Ho

AU - Ahn, Young Keun

AU - Chae, Shung Chull

AU - Hur, Seung Ho

AU - Hong, Taek Jong

AU - Kim, Young Jo

AU - Seong, In Whan

AU - Chae, Jei Keon

AU - Rhew, Jay Young

AU - Chae, In Ho

AU - Cho, Myeong Chan

AU - Bae, Jang Ho

AU - Rha, Seung-Woon

AU - Kim, Chong Jim

AU - Choi, Donghoon

AU - Jang, Yang Soo

AU - Yoon, Junghan

AU - Chung, Wook Sung

AU - Cho, Jeong Gwan

AU - Seung, Ki Bae

AU - Park, Seung Jung

PY - 2010/11/1

Y1 - 2010/11/1

N2 - The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) with or without glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with or without Gp IIb/IIIa inhibitor has not been elucidated. Between October 2005 and July 2007, 2,535 patients with ST elevation acute myocardial infarction (STEMI) undergoing PCI in the Korean Acute Myocardial Infarction Registry (KAMIR) were assigned to either of two groups: a group with Gp IIb/IIIa inhibitor (n=476) or a group without Gp IIb/IIIa inhibitor (n=2,059). These groups were further subdivided according to the use of LMWH with low dose UFH (n=219) or UFH alone (n=257). The primary end points were cardiac death or myocardial infarction during the 30 days after the registration. The primary end point occurred in 4.1% (9/219) of patients managed with LMWH during PCI and Gp IIb/IIIa inhibitor and 10.8% (28/257) of patients managed with UFH and Gp IIb/IIIa inhibitor (odds ratio [OR], 0.290; 95% confidence interval [CI], 0.132-0.634; P=0.006). Thrombolysis In Myocardial Infarction (TIMI) with major bleeding was observed in LMHW and UFH with Gp IIb/IIIa inhibitor (1/219 [0.5%] vs 1/257 [0.4%], P=1.00). For patients with STEMI managed with a primary PCI and Gp IIb/IIIa inhibitor, LMWH is more beneficial than UFH.

AB - The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) with or without glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with or without Gp IIb/IIIa inhibitor has not been elucidated. Between October 2005 and July 2007, 2,535 patients with ST elevation acute myocardial infarction (STEMI) undergoing PCI in the Korean Acute Myocardial Infarction Registry (KAMIR) were assigned to either of two groups: a group with Gp IIb/IIIa inhibitor (n=476) or a group without Gp IIb/IIIa inhibitor (n=2,059). These groups were further subdivided according to the use of LMWH with low dose UFH (n=219) or UFH alone (n=257). The primary end points were cardiac death or myocardial infarction during the 30 days after the registration. The primary end point occurred in 4.1% (9/219) of patients managed with LMWH during PCI and Gp IIb/IIIa inhibitor and 10.8% (28/257) of patients managed with UFH and Gp IIb/IIIa inhibitor (odds ratio [OR], 0.290; 95% confidence interval [CI], 0.132-0.634; P=0.006). Thrombolysis In Myocardial Infarction (TIMI) with major bleeding was observed in LMHW and UFH with Gp IIb/IIIa inhibitor (1/219 [0.5%] vs 1/257 [0.4%], P=1.00). For patients with STEMI managed with a primary PCI and Gp IIb/IIIa inhibitor, LMWH is more beneficial than UFH.

KW - Blood platelets

KW - Heparin

KW - Myocardial infarction

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=78449303538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78449303538&partnerID=8YFLogxK

U2 - 10.3346/jkms.2010.25.11.1601

DO - 10.3346/jkms.2010.25.11.1601

M3 - Article

C2 - 21060749

AN - SCOPUS:78449303538

VL - 25

SP - 1601

EP - 1608

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 11

ER -